Foundation Medicine FoundationOne RNA

Roche subsidiary Foundation Medicine has launched its FoundationOne RNA test for clinical use in the US. The tissue-based RNA sequencing test detects cancer-related fusions across 318 genes and enables reporting of fusions in all solid tumors. Foundation noted that the test may be valuable for detecting fusions in certain cancers, including non-small cell lung cancer, pancreatic cancer, cholangiocarcinoma, sarcoma, thyroid cancer, and bladder cancer. The company originally made the test available in September 2023 for research and investigational use. FoundationOne RNA can now be added to FoundationOne CDx orders for even greater confidence in fusion detection, the company noted.